April 10, 2018 10:25 AM EDT
Pharma

Biotech res­ur­rects a long fad­ed No­var­tis can­cer drug star, us­ing a bio­mark­er strat­e­gy to push ahead

John Carroll

Editor & Founder

Five years af­ter No­var­tis $NVS abrupt­ly dumped a pro­gram for its TKI dovi­tinib af­ter it failed to beat so­rafenib in a head-to-head Phase III show­down …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Lil­ly drops body mass ranges from FDA la­bel for weight loss drug

Co­herus makes fi­nal, $483M piv­ot away from biosim­i­lars

GSK ter­mi­nates Phase 2 tri­al of HBV ther­a­peu­tic vac­cine

Janux soars on ear­ly prostate can­cer da­ta that could chal­lenge No­var­tis' Plu­vic­to

Roche teams up with Chica­go au­toim­mune biotech COUR Phar­ma­ceu­ti­cals

Ipsen se­cures rights to pre­clin­i­cal T cell en­gager in $610M pact with French biotech

A service from the Financial Times